EIF4A2 and hepatocellular carcinoma: Strikingly, exposure of HCC cells to combinations of eIF4A inhibitors and the mTOR inhibitor, Rapalink-1, a third-generation mTOR inhibitor that links rapamycin and MLN0128 [48], resulted in synergistic cytostatic effects.